Discontinuing cholinesterase inhibitor showed no clear difference in dropout due to lack of efficacy of trial medication or deterioration… compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 1.53 [0.84, 2.76]
4 studies · 583 participants
Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Adverse events (any) · people with dementia

Discontinuing cholinesterase inhibitor showed no clear difference in adverse events (any) compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 0.85 [0.57, 1.27]
4 studies · 446 participants
Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

SAEs · people with dementia

Discontinuing cholinesterase inhibitor showed no clear difference in serious adverse events (SAEs) compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 0.8 [0.46, 1.39]
4 studies · 390 participants
Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Deaths · people with dementia

Discontinuing cholinesterase inhibitor showed no clear difference in deaths compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 0.75 [0.36, 1.55]
5 studies · 598 participants
Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Functional status (change from baseline, long term) BADLS · people with dementia

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 109 participants
Moderate

Rivastigmine vs placebo

Duration of delirium Days · people with delirium

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Low

Rivastigmine vs placebo

Severity of delirium CAM negative · people with delirium

The review found no eligible studies for this question.

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rivastigmine vs placebo

Adverse events: nausea · people with delirium

Cholinesterase inhibitors (rivastigmine) showed no clear difference in adverse events nausea compared with placebo (low certainty).

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
RR 0.3 [0.01, 6.29]
1 study · 15 participants
Low

Rivastigmine vs placebo

Persistent cognitive impairment · people with delirium

The review found no eligible studies for this question.

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rivastigmine vs placebo

Length of hospital stay · people with delirium

The review found no eligible studies for this question.

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rivastigmine vs placebo

All‐cause mortality · people with delirium

Cholinesterase inhibitors (rivastigmine) showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
RR 0.1 [0.01, 1.56]
1 study · 15 participants
Low

Rivastigmine vs placebo

Cost of the intervention · people with delirium

The review found no eligible studies for this question.

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylactic cholinesterase inhibitor vs placebo

Length of hospital stay

1 finding from 1 review

Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 128 participants
Low

Prophylactic cholinesterase inhibitor vs placebo

Return to independent living ‐ not measured

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found